The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.

Trial Profile

The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Eribulin (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 06 May 2016 Planned End Date changed to 1 May 2017.
    • 22 Jul 2014 Last checked against the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Nov 2014.
    • 28 Mar 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top